Factor VIII Inhibitor and Bronchogenic Carcinoma

S A D Al-Ismail; D H Parry; C U Moisey; A L Bloom

doi:10.1055/s-0038-1646648

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1979; 41(02): 291-295
DOI: 10.1055/s-0038-1646648

Original Articles

Schattauer GmbH Stuttgart

Factor VIII Inhibitor and Bronchogenic Carcinoma

S A D Al-Ismail

^*The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK

,

D H Parry

^*The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK

,

C U Moisey

^**The Department of Surgery, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK

,

A L Bloom

^*The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK

› Author Affiliations

Abstract

PDF Download

Summary

An inhibitor to procoagulant factor VIII (FVIIIC) developed in a patient three years after palliative resection of a bronchogenic carcinoma. The inhibitor was not active against ristocetin cofactor but possibly had some activity against factor XI. It responded to immunosuppressive therapy. This is apparently the first reported association of carcinoma and factor VIII inhibitor.

PDF (179 kb)

References

References
1 Biggs R, Bidwell E. 1959; A method for the study of anti-haemophilic globulin inhibitors with reference to six cases. British Journal of Haematology 5: 379
2 Biggs R, Douglas AJ. 1953; The measurement of prothrombin in plasma. Journal of Clinical Pathology 6: 15
3 Biggs R. 1976 Human Blood Coagulation, Haemostasis and Thrombosis. 2nd Edition Blackwell
4 Bloom AL, Peake IR, Giddings JC. 1973; The presence and reactions of high and lower molecular weight procoagulant factor VIII in the plasma of patients with Von Willebrand’s disease after treatment. Significance for a structural hypothesis for factor VIII Thrombosis Research 3: 389
5 Feinstein DI, Rapaport SI. 1972; Progress in Hemostasis and Thrombosis. 1: 175
6 Garner R, Conning DM. 1970; The assay of factor VII by means of a modified factor VII deficient dog plasma. British Journal of Haematology 18: 57
7 Giddings JC. 1971; Preparation and the use of a new artificial system for factor XI assay. Medical Laboratory Technology 28: 284
8 Hammonds JC, Williams JL, Fox M. 1974; The control of severe bleeding from the bladder by intravesical hyperbaric therapy. British Journal of Urology 46: 309
9 Handin RI, Martin V, Moloney WC. 1976; Antibody-induced Von Willebrand’s disease: A newly defined inhibitor syndrome. Blood 48: 393
10 Hultin MB, London FS, Shapiro SS, Young W. 1977; Heterogeneity of factor VIII antibodies: Further immunochemical and biologic studies. Blood 49: 807
11 Ingram GI C, Prentice CR M, Forbes CD, Leslie J. 1973; Low factor VIII-like antigen in acquired Von Willebrand’s syndrome and response to treatment. British Journal of Haematology 25: 137
12 Kapeller R. 1955; Das Verhalten von factor im serum unter normalen und pathologischen Bedingungen. Zeitschrift für Klinische Medizin 153: 103
13 Margolius Jr A, Jackson DP, Ratnoff OD. 1971; Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine (Baltimore) 40: 145
14 Pool Robinson. 1959; Assay of plasma antihaemophilic globulin (AHG). British Journal of Haematology 5: 17
15 Ratnoff OD, Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 31: 316
16 Stableforth P, Tamagnini GL, Dormandy KM. 1976; Acquired Von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation. British Journal of Haematology 33: 565
17 Wenz B, Friedman G. 1974; Acquired factor VIII inhibitor in a patient with malignant lymphoma. The American Journal of the Medical Sciences 268 (05) 295